Your request will be referred to the appropriate E.R. Squibb & Sons, L.L.C. medical professional, such as a Sotyktu pharmaceutical rep; Medical Science Liaison (MSL) or medical affairs.
Need to report a Sotyktu issue?
ONLINE FORMReport adverse event
Learn More
You can report a Sotyktu adverse event on MedWatch, the FDA's medical product safety reporting program for health professionals, patients and consumers.
prior authorization
Sotyktu Prior authorization resources
Complete Letter of Medical Necessity
NOT PROVIDED BY BRANDCoverage Authorization Request
Coverage Authorization Appeals
Formulary Exception Letter
Coverage Redetermination Letter
Learn More
If available, these templates are provided by the brand to help you navigate insurance, especially with newer drugs.
Benefits investigation
Sotkyu 360 Start Form
Patient Authorization - Esign Form
Learn More
Benefits investigations are conducted to determine whether a therapy is covered under a patient's insurance, if a prior authorization is required, and which specialty pharmacies are preferred.
Reimbursement help (FRM)
Receive Assistance from an FRM Regarding Reimbursement Information
Learn More
Some brands offer a field reimbursement manager who will work with your clinical staff and preferred pharmacy to help make sure patients don't fall through the cracks.
financial assistance
Sotyktu Financial assistance options
Co-pay savings program
commercial only
Sotkyu 360 Start Form
Enroll in Patient Savings Program
Patient Authorization - Esign Form
Learn More
Overview
Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance
How to sign up
Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Bridge program
commercial only
Sotkyu 360 Start Form
Bridge Program
Patient Authorization - Esign Form
Learn More
Overview
Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)
Patient benefit
100% free (outside of insurance)
Patient eligibility
HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries
How to sign up
Typically HCP assisted enrollment (via form)
Foundation programs
under insured
no insurance
goverment insurance
65+
Learn More
Overview
Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned
Patient benefit
Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted
Patient eligibility
Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.
How to sign up
Patients submit proof of out-of-pocket drug costs to charities for reimbursement
patient education
Sotyktu Patient education
Getting started on Sotyktu
NOT PROVIDED BY BRANDInstructions For Use: Plaque Psoriasis
Patient toolkit
About Sotyktu
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
View How to Take Sotyktu
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Side Effects
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Sotyktu Brochure
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Doctor Discussion Guide
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
My Experience Tracker
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Patient Resources
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Learn More
Other resources brands publish to help support patients and caregivers.
people also ask
Sotyktu FAQs
Is SOTYKTU safe to use during pregnancy?Available data from case reports on SOTYKTU use during pregnancy are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, no effects on embryo-fetal development were observed with oral administration of deucravacitinib to rats and rabbits during organogenesis at doses that were at least 91 times the maximum recommended human dose (MRHD) of 6 mg once daily. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. Report pregnancies to the Bristol-Myers Squibb Company’s Adverse Event reporting line at 1-800-721-5072.
Can SOTYKTU be used during lactation?There are no data on the presence of deucravacitinib in human milk, the effects on the breastfed infant, or the effects on milk production. Deucravacitinib is present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SOTYKTU and any potential adverse effects on the breastfed infant from SOTYKTU or from the underlying maternal condition.
Is SOTYKTU safe for use in pediatric patients?The safety and effectiveness of SOTYKTU in pediatric patients have not been established.
Is SOTYKTU safe for use in elderly patients?No overall differences in effectiveness of SOTYKTU have been observed between patients 65 years of age and older and younger adult patients. However, during the Week 0-16 period, for those subjects who received SOTYKTU without switching treatment arms, there was a higher rate of overall serious adverse reactions, including serious infections, and discontinuations due to adverse reactions compared with younger adults.
Is dosage adjustment necessary for patients with renal impairment?No dose adjustment of SOTYKTU is recommended in patients with mild, moderate, or severe renal impairment or in patients with end stage renal disease (ESRD) on dialysis.
Is dosage adjustment necessary for patients with hepatic impairment?No dose adjustment of SOTYKTU is recommended in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. SOTYKTU is not recommended for use in patients with severe hepatic impairment.
FAQ Data Source
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available
Can't find what you're looking for?
Our trained staff can help you:
Please note:
Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
Samples are provided at the discretion of the brand.
We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.